In 226 untreated patients with HER2-negative advanced gastric/GEJ cancer, adding EP4 antagonist ONO-4578 to nivolumab plus chemotherapy improved PFS vs placebo (HR 0.67, 90% CI 0.48–0.92; P=.040, α=.10). More diarrhoea and anaemia; phase II.
RCTn = 226
Nakayama et al. EP4 Antagonist ONO-4578 Plus Nivolumab and Chemotherapy in Human Epidermal Growth Factor Receptor 2-Negative Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer